Key Findings
- Purpose
The initiative seeks to address variation in ED care during vaso-occlusive episodes (VOEs) through statewide collaboration among public health, SCD clinicians, emergency medicine teams, health systems, and community partners. The North Carolina Governor’s Council on Sickle Cell Syndrome and its Medical Research Committee guide the work, with the main committee and high-ED-use subgroup meeting every other month.
- Population (Model)
Using 2013–2019 hospital-discharge data from the North Carolina Sickle Cell Data Collection program, the team identified the 20 EDs with the highest SCD visit volumes. Dissemination began with the top five EDs and expanded to the next five. Implementation includes a clinical toolbox with existing recommendations, an ED order-set template, a validated opioid calculator, a weight-based dosing chart, individualized pain-plan resources, and quality-improvement tools. Monthly expert-consultation calls and a monthly multi-institutional patient-care conference support site implementation and complex-case coordination.
- Headline Result
The report cites data indicating that 9.4% of patients accounted for 58% of ED visits. The high-ED-use subgroup established consensus-based referral criteria of at least 10 annual ED visits for adults and four for children; these thresholds are not validated definitions.
A formal coordination protocol has been established, although detailed referral and intervention processes are still being finalized. Planned supports include transportation assistance, intensive case management, and SCD education. Planned measures include time to first analgesic, medication route, triage category, referrals, admissions, and quarterly ED visits per patient. The report does not demonstrate improved care or outcomes to date. - Why It Matters
The initiative combines dissemination of clinical guidance with practical implementation support and ongoing consultation. Its staged rollout focuses first on EDs with the highest historical SCD visit volumes, while regular expert calls and a multi-institutional conference provide forums for addressing workflow challenges and coordinating complex care.
The high-ED-use subgroup adds a referral and support component beyond ED treatment protocols. Whether this model improves coordination, access, or patient outcomes remains to be evaluated. - Evidence Gaps & Limitations
The report describes an implementation effort, not a controlled evaluation of effectiveness. The utilization rankings rely on 2013–2019 data and may not reflect current ED activity. Site readiness, staffing, workflow differences, implementation fidelity, and sustainability are important issues for future evaluation, not established findings.The referral thresholds are consensus-based and unvalidated, and detailed referral and intervention processes remain under development. Evaluation is needed to assess whether the criteria identify patients who benefit from additional support and whether the proposed services are feasible and effective.
Source: Journal of Sickle Cell Disease- “A public health led, statewide approach to improving emergency department care for individuals with sickle cell disease — North Carolina”
Regulatory & Guideline Watch
The initiative draws on existing evidence-based guidance for VOE management. The 60-minute benchmark for parenteral opioid administration comes from cited clinical guidance and evidence, not a new regulatory requirement.
The toolbox and coordination protocol are implementation strategies, not new national clinical standards. Their impact on treatment timeliness, medication practices,referrals, admissions, and ED utilization will need to be assessed using the planned measures.